Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th

Rhea-AI Summary

Beyond Air, Inc. (NASDAQ: XAIR) announced it will report financial results for its fiscal first quarter on August 6, 2020, before market opening. The conference call and webcast will begin at 8:30 a.m. ET. Beyond Air focuses on developing inhaled Nitric Oxide for respiratory conditions, including severe lung infections and pulmonary hypertension. Their innovative LungFit™ device generates NO from ambient air, delivering it precisely to patients. The company is advancing clinical trials targeting infections like SARS-CoV-2 and exploring treatment options for solid tumors in pre-clinical settings.

Positive

• Active clinical trials for severe lung infections and pulmonary hypertension.
• Innovative LungFit™ device for precise delivery of Nitric Oxide.

Negative

• None.

GARDEN CITY, N.Y., July 23, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced it will report financial results for its fiscal first quarter ended June 30, 2020 before the market opens on Thursday, August 6, 2020. The Company’s management team is scheduled to host a conference call and webcast at 8:30 a.m. Eastern Time.

100%; border-collapse:collapse !important;">

Conference Call & Webcast Details:
11%; width:11%; min-width:11%;">Date and Time:	89%; width:89%; min-width:89%;">Thursday, August 6th @ 8:30 a.m. ET
Domestic:	888-220-8474
International:	323-794-2590
Passcode:	7088663
Webcast:	http://public.viavid.com/index.php?id=140846

About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, the LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. The LungFit™ can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2, bronchiolitis and nontuberculous mycobacteria (NTM).  Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system, separate from the LungFit™, to target certain solid tumors in the pre-clinical setting.  For more information, visit www.beyondair.net.

CONTACT
Steven Lisi, Chief Executive Officer
Beyond Air, Inc. 
Slisi@beyondair.net 

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com    
(212) 915-2577

FAQ

When will Beyond Air release its financial results for Q1 2020?

Beyond Air will report its financial results for the fiscal first quarter on August 6, 2020.

What is the focus of Beyond Air's clinical trials?

Beyond Air's clinical trials are focused on treating severe lung infections, including SARS-CoV-2, and pulmonary hypertension.

What is the LungFit™ device developed by Beyond Air?

The LungFit™ is an innovative device that generates Nitric Oxide from ambient air for the treatment of respiratory diseases.

What time is the Beyond Air conference call on August 6, 2020?

The conference call is scheduled for 8:30 a.m. ET on August 6, 2020.